Eleftherios P. Diamandis

Oncology · 2001–2016

A researcher in the Science corpus: 8 papers; trusts 6 researchers and is trusted by 11 researchers here, as inferred from the citation graph.

Subfields

Whom Eleftherios P. Diamandis trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. M. Washburn
  2. Padmanee Sharma
  3. D. Chace
  4. R. Aebersold
  5. S. Rosenberg

Who trusts Eleftherios P. Diamandis overall

  1. Jennifer Listgarten
  2. B. Nasseri
  3. Andrew Emili
  4. C. Alix‐Panabières
  5. N. Soleimani
  6. C. López‐Otín
  7. Navid Rabiee
  8. K. Pantel
  9. D. Fruman
  10. Prashanth Rawla

Papers from Eleftherios P. Diamandis's perspective

Ordered by how strongly the researchers Eleftherios P. Diamandis trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  3. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. (Cancer Research)
  4. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. (Proceedings of the National Academy of Sciences of the United States of America)
  5. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
  6. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
  7. Hallmarks of cancer: the next generation. (Cell)
  8. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (Molecular and Cellular Biology)
  9. Molecular portraits of human breast tumours (Nature)
  10. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (Journal of Experimental Medicine)

Their papers